Crispr Therapeutics AG (CRSPN) Stock Price & Analysis
CRSPN Stock Chart & Stats
- Day’s Range
- MXN 900.00 - MXN 950.00
- 52-Week Range
- MXN 750.00 - MXN 1,375.00
- Previous Close
- MXN 915.00
- Volume
- 400
- Average Volume (3M)
- 36
- Market Cap
- MXN 93.43B
- Enterprise Value
- MXN 3.68B
- Total Cash (Recent Filing)
- MXN 2.36B
- Total Debt (Recent Filing)
- MXN 783.75M
- Price to Earnings (P/E)
- ―
- Beta
- -0.11
- Next Earnings
- Nov 04, 2026 (Est.)
- EPS Estimate
- -19.49
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
CRISPR Gene-editing Platform And Diversified Pipeline
A focused CRISPR/Cas9 platform applied across multiple therapeutic areas gives CRISPR Therapeutics a reusable scientific foundation rather than dependence on one candidate. A broader pipeline can create several paths to clinical advancement, partnerships and future commercialization over the next several quarters.
Relative Balance-sheet Strength
Sizable equity relative to debt provides a comparatively stronger financial base while the company funds research and clinical development. Moderate overall leverage can preserve financing flexibility and improve resilience as management works toward approvals, partnerships or more sustainable operating performance.
Internal CFO Succession And Orderly Transition
Promoting an experienced internal finance executive can preserve institutional knowledge and reduce disruption in financial oversight. The stated transition support from the departing CFO also helps maintain continuity in reporting and controls during a period when disciplined capital management remains important.
Bears Say
Negative Gross Profit And Substantial Losses
Negative gross profit and large operating and net losses show that current economics do not yet support self-sustaining profitability. This limits internal funding for research and commercialization, increases dependence on financing or partners, and makes future earnings power highly dependent on clinical and commercial execution.
Persistent Cash Burn And Funding Needs
Materially negative operating and free cash flow indicate that the business continues to consume cash while advancing its pipeline. The multi-year pattern since 2022 implies ongoing funding needs, which can constrain strategic flexibility and require additional capital before operations improve.
Highly Volatile Earnings Base
The shift from strong profitability in 2021 to multi-year losses demonstrates an uneven earnings base and limited margin stability. Such volatility makes operating outcomes harder to plan, weakens confidence in near-term earnings durability, and leaves results sensitive to development or partnership timing.
Crispr Therapeutics AG News
CRSPN FAQ
What was Crispr Therapeutics AG’s price range in the past 12 months?
What is Crispr Therapeutics AG’s market cap?
When is Crispr Therapeutics AG’s upcoming earnings report date?
How were Crispr Therapeutics AG’s earnings last quarter?
Is Crispr Therapeutics AG overvalued?
Does Crispr Therapeutics AG pay dividends?
What is Crispr Therapeutics AG’s EPS estimate?
How many shares outstanding does Crispr Therapeutics AG have?
What happened to Crispr Therapeutics AG’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Crispr Therapeutics AG?
What is the TipRanks Smart Score and how is it calculated?
Crispr Therapeutics AG Stock Smart Score
Company Description
Crispr Therapeutics AG
CRISPR Therapeutics AG (CRSP) is a biotechnology firm dedicated to pioneering gene-based medicines for severe diseases. The company achieves this through its exclusive Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) technology, which enables precise and targeted alterations to an organism's genetic code. Its extensive pipeline includes therapeutic candidates spanning multiple medical areas, such as blood disorders (hemoglobinopathies), various cancers (oncology), regenerative medicine, and rare conditions. The company's flagship investigational therapy is CTX001, an ex vivo CRISPR gene-edited treatment. This therapy aims to benefit patients with transfusion-dependent beta-thalassemia or severe sickle cell disease by modifying their own hematopoietic stem cells to markedly boost the production of fetal hemoglobin within red blood cells. CRISPR Therapeutics is also advancing several other genetically engineered allogeneic (donor-sourced) CAR-T investigational therapies: CTX110, designed to combat cluster of differentiation 19-positive malignancies; CTX120, which targets B-cell maturation antigen for multiple myeloma that has relapsed or proven resistant to previous treatments; and CTX130, focused on Cluster of Differentiation 70 for a spectrum of solid tumors and blood cancers. Furthermore, the company is developing VCTX210, an immune-evasive, gene-edited stem cell-derived product candidate for treating type 1 diabetes. It is also pursuing various in vivo gene-editing initiatives aimed at addressing disorders affecting the liver, lungs, muscles, and central nervous system. The company has forged strategic alliances with significant partners, including Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was established in 2013 and maintains its headquarters in Zug, Switzerland.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Samarth Kulkarni
- Employees
- 393
- Website
- www.crisprtx.com
- Address
- Baarerstrasse 14, Zug, ZG, 6300, CH
Crispr Therapeutics AG (CRSPN) Earnings & Revenues
CRSPN Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 4 | 4 | 14 |
| Technical Analysis | 4 | 4 | 2 |
| Moving Averages | 0 | 0 | 12 |
